Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Cardiology"
DOI: 10.1001/jamacardio.2017.2959
Abstract: Overview Pay-for-performance programs, which seek to better align incentives between insurers and clinicians, are increasingly being used to improve quality without necessarily increasing spending. For example, under Medicare’s hospital value-based payment program, reimbursements are based… read more here.
Keywords: pcsk9 inhibitors; based pricing; outcomes based; reimbursement ... See more keywords
Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.
Sign Up to like & getrecommendations! Published in 2025 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2025.0195
Abstract: Importance Despite substantial progress in low-density lipoprotein cholesterol (LDL-C)-lowering strategies, residual cardiovascular risk remains. Apolipoprotein C3 (APOC3) has emerged as a novel target for lowering triglycerides. Multiple clinical trials of small-interfering RNA therapeutics targeting APOC3… read more here.
Keywords: risk; chd; apoc3; pcsk9 ... See more keywords
PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.30581
Abstract: Cardiovascular disorders are still challenging and are among the deadly diseases. As a major risk factor for atherosclerotic cardiovascular disease, dyslipidemia, and high low‐density lipoprotein cholesterol in particular, can be prevented primary and secondary by… read more here.
Keywords: cardiovascular disease; pcsk9; pcsk9 inhibitors; design ... See more keywords
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.30025
Abstract: Proprotein convertase subtilisin/kexin type‐9 (PCSK9), a member of the proprotein convertase family, is an important drug target because of its crucial role in lipid metabolism. Emerging evidence suggests a direct role of localized PCSK9 in… read more here.
Keywords: vascular disease; physiology; role; pcsk9 ... See more keywords
Regression of carotid atherosclerosis in high-risk individuals with proprotein convertase subtilisin/kexin type 9 inhibitors.
Sign Up to like & getrecommendations! Published in 2025 at "Lipids"
DOI: 10.1002/lipd.12432
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a novel approach for reducing cholesterol and, accordingly, the burden of atherosclerosis. However, limited data are available regarding the possible effects of PCSK9 inhibitors on atherosclerotic plaque.… read more here.
Keywords: convertase subtilisin; atherosclerosis; risk; high risk ... See more keywords
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
Sign Up to like & getrecommendations! Published in 2017 at "Basic Research in Cardiology"
DOI: 10.1007/s00395-017-0619-0
Abstract: Ischemic heart disease is the main cause of death worldwide and is accelerated by increased levels of low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a potent circulating regulator of LDL-C through… read more here.
Keywords: regulation pcsk9; pcsk9 activity; pcsk9; disease ... See more keywords
Statin Pharmacology Revisited
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-06951-9
Abstract: We read with interest the review on statins by Azemawah and colleagues, but we considered that there were certain important errors and omissions [1]. The authors provided several conflicting statements about the association of new… read more here.
Keywords: risk; study; statin; drug ... See more keywords
Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases
Sign Up to like & getrecommendations! Published in 2018 at "Current Cardiology Reports"
DOI: 10.1007/s11886-018-0993-8
Abstract: Purpose of ReviewThis review aims to explore and summarize the current literature on the cardiovascular disease (CVD) healthcare burden and determine the cost-effectiveness of the PCSK9 inhibitors.Recent FindingsThe CVD remain the largest cause of mortality… read more here.
Keywords: cost effectiveness; pcsk9 inhibitors; pcsk9; cvd ... See more keywords
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Current Cardiology Reports"
DOI: 10.1007/s11886-019-1103-2
Abstract: Purpose of ReviewTo review the clinical rationale for use of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors in clinical practice.Recent FindingsDespite widespread use of statins for lipid lowering, many patients at high cardiovascular risk… read more here.
Keywords: new face; risk; pcsk9 inhibitors; face hyperlipidemia ... See more keywords
Induced Human-like Coronary Stenosis in Hypercholesterolemic PCSK9 Minipigs
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Cardiovascular Translational Research"
DOI: 10.1007/s12265-025-10607-0
Abstract: Translational models for obstructive coronary artery disease are lacking. We aimed to develop a porcine model for obstructive coronary stenosis induced by bioresorbable stent (BRS) implantation in hypercholesterolemic proprotein convertase subtilisin/kexin-9 (PCSK9) minipigs. Fifteen hypercholesterolemic… read more here.
Keywords: pcsk9 minipigs; human like; pcsk9; coronary stenosis ... See more keywords
Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0867-9
Abstract: The clinical importance and benefit of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors appears well established for the high-risk cardiovascular (CV) patient. This applies especially to the statin-intolerant patient or the patient who does… read more here.
Keywords: outcomes access; pcsk9 inhibitors; ldl; cholesterol ... See more keywords